Category: St. Jude Medical
Say hello to MassDevice +7, a bite-sized view of the top seven med-tech stories of the week. This latest feature of MassDevice.com's coverage highlights our seven biggest and most influential stories from the week's news to make sure you're up to date on the headlines that continue to shape the medical device industry.
Regulators in the European Union green-light St. Jude Medical's Ilumien Optis 3D vessel reconstruction technology to guide coronary stent placement.
St. Jude Medical (NYSE:STJ) today announced CE Mark approval of its Ilumien Optis PCI optimization system, designed to help physicians assess and treat patients with coronary artery disease.
St. Jude Medical begins enrollment in the Elightn III trial of its renal denervation device for treating high blood pressure.
The 1st patient enrolled today in a St. Jude Medical (NYSE:STJ)-sponsored trial to evaluate the safety and performance of a new renal denervation system in patients with drug-resistant, uncontrolled hypertension, the company said.
Medical device giant St. Jude Medical wins CE Mark approval in the European Union for 2 defibrillator product portfolios designed to reduce lead abrasion, the most common type of lead insulation failure.
St. Jude Medical (NYSE:STJ) won European regulatory approval for 2 next-generation defibrillators, the Ellipse and the SJM Assura high voltage systems. The new devices aim to bolster device reliability by preventing lead-to-can abrasion, according to the company.
St. Jude Medical's shares ticked up today after an independent research team reported 99.4% freedom from all-cause mechanical failure at 5 years for the company's next-generation Durata defibrillator leads.
Medical device giant St. Jude Medical (NYSE:STJ) landed an important win today after a research team released study results finding that the company's Durata defibrillator leads proved safe and reliable in an independent review.
A small study presented at the Heart Rhythm Society's annual meeting in Denver yesterday shows that, although St. Jude Medical's recalled QuickSite and QuickFlex cardiac rhythm therapy leads failed in nearly half of patients, there was no sign that their heart failure got any worse.
The U.S. Justice Dept. closes an investigation into St. Jude Medical's recalled Riata defibrillators leads without charging the company with allegations of misconduct.
Healthcare giant St. Jude Medical (NYSE:STJ) revealed in a recent regulatory filing that U.S. Justice Dept. investigators closed a probe of the recalled Riata and Riata ST defibrillators leads.
